MediciNova heads toward summer topline data for tipelukast in diabetic NAFLD
The Phase 2 trial closed enrollment at its 40-patient target, leaving co-primary liver-fat and triglyceride results as the next test for a mechanism with no direct precedent.
Executive Summary
- MediciNova has closed enrollment in its Phase 2 trial of tipelukast for diabetic patients with hypertriglyceridemia and fatty liver disease, and topline results are expected within the next several months.
- The trial asks whether a single oral compound can move both liver fat and triglycerides in the same diabetic population, co-primary endpoints that, if both move together, would support the drug's stated multi-mechanism rationale.
- No other clinical-stage program targets this same receptor in this disease combination, so the result will be read against older PDE4-inhibitor data in adjacent liver and metabolic settings rather than against a direct rival.
- The sponsor's guidance for a summer 2026 readout has held steady across five successive updates since November 2025, and the trial's completed enrollment removes recruitment as a source of delay risk.
The catalyst
MediciNova expects to report topline data from MN-001-NATG-202, a Phase 2 trial of MN-001 (tipelukast) in patients with hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) tied to type 2 diabetes, by the summer of 2026. The trial is registered as NCT05464784 and is listed as Active, not recruiting. The company has repeated the same third-quarter 2026 topline timeline across guidance issued in November 2025, January 2026, May 2026 and June 2026, with one December 2025 update widening the window to the second half of 2026 before returning to the Q3 framing. MediciNova+1MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of ...Nov 4, 2025MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial measures
The study is a multi-center, randomized, double-blind, placebo-controlled design that assigns patients 1:1 to 500 mg per day of tipelukast or placebo for 24 weeks. The co-primary endpoints are the mean change from baseline in liver fat content, measured by controlled attenuation parameter (CAP) score on sound-based elastography, and the mean change from baseline in fasting serum triglycerides, both at Week 24. Secondary endpoints cover safety, tolerability, and changes in HDL-C, LDL-C and total cholesterol. Enrollment eligibility required a CAP score of at least 248 dB/m and fasting triglycerides above 150 mg/dL at screening, targeting a population with confirmed liver fat and lipid abnormality rather than a broader diabetic cohort. MediciNova+1MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of ...Nov 4, 2025MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784
Enrollment and operations
MediciNova announced completion of patient enrollment in the trial on November 4, 2025, closing recruitment at the planned 40-patient target. The trial's registered enrollment figure has not changed from that 40-patient target, a routine outcome that removes recruitment risk from the readout timeline. The primary completion date has moved twice, first from June 2024 to December 2025 in November 2024, then from December 2025 to December 2026 in February 2026, alongside the status change to Active, not recruiting. That primary completion date, December 31, 2026, sits after the company's stated third-quarter topline window, reflecting that full follow-up and database lock for the registered endpoints extends beyond the earlier top-line data cut the company has guided to. MediciNova+1MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of ...Nov 4, 2025MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaNCT05464784
The competitive frame
No other industry-sponsored trial currently tests a BLT1 antagonist in NAFLD, and no company-sponsored program shares both the target and this diabetic-NAFLD-hypertriglyceridemia combination. The nearest mechanistic precedent is a PDE4 inhibitor, Astellas Pharma's ASP9831, tested in a proof-of-principle non-alcoholic steatohepatitis study more than a decade ago, alongside older PDE4-inhibitor work in type 2 diabetes such as AstraZeneca's roflumilast study. Later-stage competition in fatty liver disease is now dominated by GLP-1 and FGF21-pathway agents, including Novo Nordisk's semaglutide and 89bio's pegozafermin, which work through different mechanisms and are not direct comparators to tipelukast's leukotriene- and phosphodiesterase-linked pathway.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.